Monitoring safety and use of old and new treatment options for type 2 diabetic patients: a two-year (2013-2016) analysis

Expert Opin Drug Saf. 2016 Dec;15(sup2):17-34. doi: 10.1080/14740338.2016.1246531.

Abstract

Objective: To compare patients' and physicians' perceptions regarding effectiveness and tolerability of non-insulin hypoglycemic drugs in a cohort of type 2 diabetic patients; to verify whether a possible tridimensional link between effectiveness, tolerability, and adherence affects long-term therapeutic outcomes.

Methods: A two-year observational study was performed in 1389 Type 2 diabetic patients by involving general practitioner clinics and Diabetes Centers. A decimal scale and the Morisky questionnaire were used, respectively, to assess effectiveness and tolerability perceptions, and medication adherence.

Results: Physicians perceived therapy as more efficacious compared to their patients: perceived effectiveness was steady for physicians during the study whereas patients' perception not significantly decreased (mean score from >8 to 7.84 ± 1.69). Physicians assigned higher tolerability scores compared to patients but only at the beginning of the study; interestingly, physicians' tolerability perception was poorer than patients' perception at last follow-up (mean score = 7.57 ± 1.40 vs. 7.88 ± 1.84). Favorable (score >7) patients' perceptions about treatment effectiveness and tolerability were associated with higher adherence. Patients showed medium adherence across the study.

Conclusions: A mutual relationship between clinical effectiveness, adverse drug reactions, and adherence has been established, significantly impacting the clinical management of diabetic patients. A careful monitoring of this link by clinicians appears therefore necessary.

Keywords: Adverse drug reactions; Morisky scale; clinical effectiveness; medication adherence; non-insulin hypoglycemic drugs; type 2 diabetes mellitus.

Publication types

  • Multicenter Study
  • Observational Study

MeSH terms

  • Aged
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Female
  • Follow-Up Studies
  • Humans
  • Hypoglycemic Agents / adverse effects
  • Hypoglycemic Agents / therapeutic use*
  • Male
  • Medication Adherence*
  • Middle Aged
  • Prospective Studies
  • Retrospective Studies
  • Surveys and Questionnaires
  • Treatment Outcome

Substances

  • Hypoglycemic Agents